Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia, a type of blood cancer, and proved effective in animal models of the disease.
Back to News
Weill Cornell MedicineOffice of External Affairs
1300 York AvenueBox 314
New York, NY 10065
Phone: (646) 962-9476